Versant Venture Capital VII L.P. 13D and 13G filings for Chinook Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-03-10 4:13 pm Sale |
2023-03-01 | 13D | Chinook Therapeutics, Inc. KDNY |
Versant Venture Capital VII L.P. | 2,105,107 3.200% |
-240,000 (-10.23%) |
Filing |
| 2022-12-28 4:07 pm Sale |
2022-12-22 | 13D | Chinook Therapeutics, Inc. KDNY |
Versant Venture Capital VII L.P. | 2,345,107 3.700% |
-567,963 (-19.50%) |
Filing |
| 2022-08-22 4:15 pm Unchanged |
2022-08-12 | 13D | Chinook Therapeutics, Inc. KDNY |
Versant Venture Capital VII L.P. | 2,913,070 4.600% |
0 (Unchanged) |
Filing |
| 2022-04-13 4:43 pm Sale |
2022-04-04 | 13D | Chinook Therapeutics, Inc. KDNY |
Versant Venture Capital VII L.P. | 2,913,070 5.300% |
-709,953 (-19.60%) |
Filing |
| 2022-01-13 4:30 pm Sale |
2022-01-03 | 13D | Chinook Therapeutics, Inc. KDNY |
Versant Venture Capital VII L.P. | 3,623,023 6.700% |
-600,000 (-14.21%) |
Filing |
| 2021-09-07 5:13 pm Sale |
2021-08-27 | 13D | Chinook Therapeutics, Inc. KDNY |
Versant Venture Capital VII L.P. | 4,223,023 9.400% |
-510,000 (-10.78%) |
Filing |
| 2020-10-15 5:16 pm Purchase |
2020-10-05 | 13D | Chinook Therapeutics, Inc. KDNY |
Versant Venture Capital VII L.P. | 4,733,023 11.200% |
4,733,023 (New Position) |
Filing |